Adding value to blood cell counting through AI image analysis, system integration and data integration
First written in FY2021. 4 of 7 entries say "Advanced", first in FY2022-Q1. Latest entry: 2026-10-01.
No other company in this theme has enough history to compare yet.
- 2026-10-01AdvancedGovernance
「We are also developing a web application to support customer care activities generally by using AI models to determine equipment status and visualize equipment log data.」
The scope of testing data and AI utilization was expanded beyond test-result analysis to include equipment-status determination, predictive maintenance and the digitalization of customer care. - FY2026AdvancedAnnual report
「In addition, amid the increasing sophistication of healthcare in recent years, the company will promote laboratory automation to improve productivity and address the worsening shortage of laboratory technologists by further automating testing processes and developing systems that use AI to analyze test results.」
The company made its policy on AI image analysis, system integration and data integration more concrete through the development of test-result analysis systems, end-to-end laboratory automation and measures to address the shortage of laboratory technologists. - FY2023AdvancedAnnual report
「The company will also pursue the creation of new diagnostic solutions for hematologic malignancies, cancer, hereditary diseases and age-related diseases by combining existing testing technologies and applying data science.」
The company expanded its direction for adding value through AI and data integration to the creation of diagnostic solutions across multiple disease areas using combinations of existing testing technologies and data science. - FY2022-Q3RestatedAnnual report
「② May 2021: The company entered into an agreement with ThinkCyte K.K. for joint development and a capital alliance aimed at commercializing AI-based cell analysis technology.」
The company has restated its agreement with ThinkCyte K.K. for the joint development and capital alliance of AI-based cell analysis technology. - FY2022-Q2RestatedAnnual report
「May 2021: The company entered into an agreement with ThinkCyte K.K. for joint development and a capital alliance aimed at commercializing AI-based cell analysis technology.」
The company has restated its agreement with ThinkCyte K.K. for the joint development and capital alliance of AI-based cell analysis technology. - FY2022-Q1AdvancedAnnual report
「May 2021: The company entered into an agreement with ThinkCyte K.K. for joint development and a capital alliance aimed at commercializing AI-based cell analysis technology.」
The company entered into agreements with ThinkCyte K.K. for the joint development and capital alliance of AI-based cell analysis technology, making its commercialization initiatives more concrete. - FY2021First statedAnnual report
「In the blood cell counting testing field, in addition to introducing the XR Series of Automated Multi-Parameter Hematology Analyzers and the XQ Series of Automated Multi-Parameter Hematology Analyzers, we aim to deliver new value by using AI-based image analysis, system integration and data integration to support earlier definitive diagnoses and the selection of appropriate treatment plans.」
The company outlined initiatives to provide new value in the blood cell counting field by using AI-based image analysis, system integration and data integration to support definitive diagnoses and treatment decisions.